Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Study of Safety and Effectiveness of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Plaque-type Psoriasis

ClinicalTrials.gov ID: NCT00267969

Public ClinicalTrials.gov record NCT00267969. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 9:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Multicenter, Randomized, Double-blind, Placebo Controlled Trial Evaluating the Efficacy and Safety of Ustekinumab (CNTO 1275) in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary purpose of this study is to evaluate the effectiveness and safety of ustekinumab (CNTO 1275) in the treatment of patients with moderate to severe plaque psoriasis.

Study identification

NCT ID
NCT00267969
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Enrollment
766 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 2005 (Type not available)
Primary completion
Jul 2006 (Actual)
Completion
May 2011 (Actual)
Last update posted
Jun 17, 2013

2005 – 2011

United States locations

U.S. sites
28
U.S. states
23
U.S. cities
28
Facility City State ZIP Site status
Not listed Phoenix Arizona — —
Not listed Los Angeles California — —
Not listed Redwood City California — —
Not listed Santa Monica California — —
Not listed Denver Colorado — —
Not listed Wilmington Delaware — —
Not listed Ocala Florida — —
Not listed Alpharetta Georgia — —
Not listed Marietta Georgia — —
Not listed Newnan Georgia — —
Not listed Honolulu Hawaii — —
Not listed Boise Idaho — —
Not listed Normal Illinois — —
Not listed Indianapolis Indiana — —
Not listed Lake Charles Louisiana — —
Not listed Worcester Massachusetts — —
Not listed Fridley Minnesota — —
Not listed St Louis Missouri — —
Not listed Omaha Nebraska — —
Not listed East Windsor New Jersey — —
Not listed Albuquerque New Mexico — —
Not listed New York New York — —
Not listed Lake Oswego Oregon — —
Not listed Portland Oregon — —
Not listed Goodlettsville Tennessee — —
Not listed Dallas Texas — —
Not listed Seattle Washington — —
Not listed Milwaukee Wisconsin — —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 14 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00267969, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 17, 2013 · Synced Oct 29, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00267969 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →